Vibe Bio provides VibeOne, an AI‑driven due‑diligence platform that automatically ingests and structures global unstructured data—such as patents, clinical trials, and scientific literature—to map the full therapeutic asset landscape. The platform uses multimodal large language models to generate probabilistic risk scores, competitive benchmarks, and real‑time updates, enabling biopharma strategy and business development teams to prioritize high‑potential programs in days instead of months.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OICFounders
Product
Problem
Biopharma business development and portfolio teams must evaluate thousands of drug assets across global markets, but manual data gathering and expert analysis are time‑consuming, resource‑intensive, and prone to gaps, leading to delayed decisions and missed opportunities.
Solution
Vibe Bio offers VibeOne, an AI‑driven due‑diligence platform that ingests internal and external unstructured data, structures it, and runs multimodal large language models to map the full landscape of therapeutic assets. The system provides instant probabilistic scoring of development risk, competitive benchmarking, and real‑time risk analysis, enabling users to prioritize high‑potential programs within days instead of months. Expert‑reviewed reports align with defined strategic criteria, while the platform continuously tracks scientific updates and regulatory changes to keep analyses current. By automating data synthesis and applying validated AI analytics, VibeOne reduces subject‑matter workload, accelerates decision timelines, and improves the precision of portfolio and in‑licensing choices.
Target Audience
Primary users are Chief Strategy Officers, Business Development, and In‑licensing teams at biopharma companies seeking faster, data‑driven asset evaluation and portfolio prioritization.
Features
- Automated ingestion and structuring of global unstructured data sources, including patents, clinical trial records, and scientific literature
- Multimodal large language model analysis that generates probabilistic success scores and risk assessments for each asset
- Real‑time landscape mapping with instant identification of new indications, competitors, and expansion opportunities
- Customizable query interface to define strategic goals, criteria, and evaluation parameters
- Expert‑reviewed, AI‑augmented reports delivering deep scientific and clinical assessments aligned to user strategy
- Continuous monitoring of catalysts and regulatory updates to keep analyses up‑to‑date
- Integration workflow that supports collaboration between business development, strategy, and in‑licensing teams